Osteoporosis is a disease marked by reduced bone mass, leading to an increased risk of fractures or broken bones. Bone formation is mediated by recruiting mesenchymal stem cells (MSCs). Elucidation of the molecular mechanisms that regulate MSC differentiation into osteoblasts is of great importance for the development of anabolic therapies for osteoporosis and other bone metabolism-related diseases. microRNAs (miRNAs) have been reported to have crucial roles in bone development, osteogenic differentiation and osteoporosis pathophysiology. However, to date, only a few miRNAs have been reported to enhance osteogenesis and regulate the suppressive effect of glucocorticoids on osteogenic differentiation. In this study, we discovered that miR-216a, a pancreatic-specific miRNA, was significantly upregulated during osteogenic differentiation in human adiposederived MSCs (hAMSCs). The expression of miR-216a was positively correlated with the expression of bone formation marker genes in clinical osteoporosis samples. Functional analysis demonstrated that miR-216a can markedly promote osteogenic differentiation of hAMSCs, rescue the suppressive effect of dexamethasone (DEX) on osteogenic differentiation in vitro and enhance bone formation in vivo. c-Cbl, a gene that encodes a RING finger E3 ubiquitin ligase, was identified as a direct target of miR-216a. Downregulation of c-Cbl by short hairpin RNAs can mimic the promotion effects of miR-216a and significantly rescue the suppressive effects of DEX on osteogenesis. Pathway analysis indicated that miR-216a regulation of osteogenic differentiation occurs via the c-Cbl-mediated phosphatidylinositol 3 kinase (PI3K)/AKT pathway. The recovery effects of miR-216a on the inhibition of osteogenesis by DEX were attenuated after blocking the PI3K pathway. Thus, our findings suggest that miR-216a may serve as a novel therapeutic agent for the prevention and treatment of osteoporosis and other bone metabolism-related diseases.
Osteoporosis is a disease marked by reduced bone mass, leading to an increased risk of fractures or broken bones. Bone formation is mediated by recruiting mesenchymal stem cells (MSCs). Elucidation of the molecular mechanisms that regulate MSC differentiation into osteoblasts is of great importance for the development of anabolic therapies for osteoporosis and other bone metabolism-related diseases. microRNAs (miRNAs) have been reported to have crucial roles in bone development, osteogenic differentiation and osteoporosis pathophysiology. However, to date, only a few miRNAs have been reported to enhance osteogenesis and regulate the suppressive effect of glucocorticoids on osteogenic differentiation. In this study, we discovered that miR-216a, a pancreatic-specific miRNA, was significantly upregulated during osteogenic differentiation in human adiposederived MSCs (hAMSCs). The expression of miR-216a was positively correlated with the expression of bone formation marker genes in clinical osteoporosis samples. Functional analysis demonstrated that miR-216a can markedly promote osteogenic differentiation of hAMSCs, rescue the suppressive effect of dexamethasone (DEX) on osteogenic differentiation in vitro and enhance bone formation in vivo. c-Cbl, a gene that encodes a RING finger E3 ubiquitin ligase, was identified as a direct target of miR-216a. Downregulation of c-Cbl by short hairpin RNAs can mimic the promotion effects of miR-216a and significantly rescue the suppressive effects of DEX on osteogenesis. Pathway analysis indicated that miR-216a regulation of osteogenic differentiation occurs via the c-Cbl-mediated phosphatidylinositol 3 kinase (PI3K)/AKT pathway. The recovery effects of miR-216a on the inhibition of osteogenesis by DEX were attenuated after blocking the PI3K pathway. Thus, our findings suggest that miR-216a may serve as a novel therapeutic agent for the prevention and treatment of osteoporosis and other bone metabolism-related diseases. Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility. 1 With the advent of a large aging population, as well as the wide clinical use of glucocorticoids, osteoporosis has become the 'invisible killerʹ in a large part of the population. Senile osteoporosis and postmenopausal osteoporosis are the main types of primary osteoporosis. Glucocorticoids are frequently used to treat inflammatory and autoimmune disorders. However, long-term administration of glucocorticoids has several adverse effects, of which osteoporosis is one with a high incidence and a wide range of damaging effects. Glucocorticoids are the leading cause of secondary osteoporosis. Glucocorticoids suppress bone formation and osteoblastgenesis through their direct and indirect effects on osteoblasts, osteoclasts and osteocytes, increasing bone resorption and eventually leading to a negative bone balance. 2, 3 So far, there are no effective preventive measures for glucocorticoid-induced osteoporosis (GIO).
Bone formation is mediated by recruiting mesenchymal stem cells (MSCs), which then differentiate into osteoblasts. MSCs, which are present in the stroma of virtually all mammalian organs, particularly in the bone marrow and subcutaneous fat, [4] [5] [6] [7] can differentiate into osteoblasts, adipocytes and chondrocytes. 8, 9 It has been previously reported that the osteoblast number declines remarkably during ageing or osteoporosis, the loss of which is accompanied by a significant decrease in transcripts for mesenchymal cells and osteoprogenitor markers, as well as a reduction in bone mass. 10, 11 Thus, the identification of factors that regulate the osteogenic differentiation of MSCs is an area of intensive investigation with the potential for identifying novel targets to enhance bone formation for osteoporosis. microRNAs (miRNAs) are highly conserved, small (~22 nucleotides long), single-stranded endogenous noncoding RNAs that have been identified as regulators of diverse biological processes, such as cell proliferation, cell cycle, differentiation, organ development, cancer and hormone secretion.
12-16 miRNAs typically regulate gene expression at the post-transcriptional level by promoting mRNA degradation and/or inhibiting mRNA translation through binding to complementary sequences in the 3ʹ-untranslated region (3ʹUTR) of the target mRNAs. 17, 18 It has been reported that~30% of human protein-coding genes are regulated by miRNAs, indicating the essential role of miRNAs in regulating gene expression. 19, 20 A growing body of evidence has suggested that miRNAs have crucial roles in different aspects of bone development, osteogenic differentiation and osteoporosis pathophysiology. 21 Several miRNAs (e.g., miR-133, miR-135, miR-138, miR-34s, miR-1192, miR-214, miR-34a and miR--542a-3p) have been reported to be negative regulators of osteogenic differentiation and bone formation through their targeting of the osteogenic master transcription factors RUNX2 (runt-related transcription factor), osterix (OSX) or other osteogenic-related genes. [22] [23] [24] [25] [26] [27] [28] [29] In addition, a few miRNAs have been identified to function as 'molecular switchesʹ responsible for the balance of MSC differentiation to osteoblasts versus adipocytes. For example, miR-204, miR-17-5p and miR-106a suppress osteoblast differentiation and promote adipocyte differentiation, whereas miR-637 has the opposite effects. [30] [31] [32] However, to date, only a few miRNAs have been reported to be antagonists for the suppression of glucocorticoids during osteogenic differentiation. 33, 34 In this study, we revealed that miR-216a promotes the osteogenic differentiation of human adipose-derived MSCs (hAMSCs) in vitro and enhances bone formation in vivo. Moreover, we demonstrated that a high concentration of dexamethasone (DEX) inhibits osteogenic differentiation, whereas miR-216a antagonizes the suppressive effect of DEX on osteogenic differentiation. c-Cbl, a gene encoding a RING finger E3 ubiquitin ligase, was identified as a direct target of miR-216a. Pathway analysis indicates that the promotion of miR-216a in osteogenic differentiation occurs by regulating the c-Cbl-mediated phosphatidylinositol 3 kinase (PI3K)/AKT pathway. Importantly, downregulation of c-Cbl can also significantly attenuate the suppressive effect of DEX on osteogenic differentiation of hAMSCs. The recovery effects of miR-216a on the inhibition of osteogenic differentiation by DEX are attenuated by blocking the PI3K pathway. Our findings suggest that miR-216a may serve as a novel therapeutic agent for the prevention and treatment of osteoporosis and other bone metabolism-related diseases.
Results
Expression pattern of miR-216a. miRNA arrays were conducted to identify miRNAs that are associated with the osteogenic differentiation of hAMSCs. Expression pattern of miRNAs were compared between osteogenic-induced 4-day cells and undifferentiated-hAMSCs. According to fold change and P-values, we selected 12 significantly upregulated miRNAs to investigate the function (Figure 1a and Supplementary Table S1 ). We found some of these miRNAs can promote osteogenic differentiation, among which the promoting effect of miR-216a was most significant, thus we chose miR-216a in follow-up experiments. TaqMan quantitative real-time PCR (qRT-PCR) further confirmed that miR-216a sharply increased when hAMSCs underwent osteogenic differentiation (Figure 1b) . Sequence analysis of the miR-216a revealed that it is highly conserved in Homo sapiens, Mus musculus, Rhesus macaque, Danio rerio, Pan troglodytes, Pongo pygmaeus and Capitella teleta (Figure 1c) . Based on further qRT-PCR analysis of various mouse tissues, miR-216a exhibited low expression in several tissues (e.g., lung, liver, heart, kidney and colon), whereas it was highly expressed in pancreas, osteogenic progenitors and osteoblasts (Figure 1d) . Similarly, miR-216a expression in several ordinary cell lines was also much lower than that in osteoblasts (Figure 1e ). miR-216a regulates osteogenic differentiation in vitro and bone formation in vivo. To investigate the roles of miR-216a in the regulation of osteogenic differentiation, we inhibited the endogenous expression of miR-216a in hAMSCs by antagomir ( Figure 2a ) and then induced miR-216a antagomir (anta-216a)-transfected or negative control antagomir (anta-NC)-transfected hAMSCs to differentiate into the osteogenic lineage. qRT-PCR and western blot analyses showed that mRNA and protein levels of the osteogenic transcription factors and marker genes alkaline phosphatase (ALP), osteopontin (OPN), RUNX2, COL1A1 and IBSP were significantly decreased in anta-216a-transfected hAMSCs compared with anta-NC-transfected cells during osteogenic differentiation (Figures 2b and c) . Repressed ALP staining and ALP activity (Figures 2d and e) , as well as decreased mineral deposition detected by Alizarin red staining (Figure 2f ), further indicated that inhibition of miR-216a significantly suppressed the osteogenic differentiation of hAMSCs.
We next infected hAMSCs with lenti-miR-216a (lenti-216a) or lenti-miR-negative control (lenti-NC) and purified them with puromycin. The intracellular miR-216a levels were remarkably upregulated following lenti-216a infection (Figure 3a To investigate the role of miR-216a in vivo, a preclinical ectopic bone formation model in NOD/SCID mice was used. Uninfected hAMSCs and lenti-216a-or lenti-NC-infected hAMSCs were loaded onto hydroxyapatite/tricalcium phosphate (HA/TCP) scaffolds, respectively, and implanted subcutaneously into NOD/SCID mice for 8 weeks. Hematoxylin and eosin (H&E) staining revealed a remarkable increase in the quantity and size of osteoids in the mouse grafts with lenti-216a-infected hAMSCs, whereas no obvious osteoids miR-216a affects osteogenesis by targeting c-Cbl
were detected in the grafts with either lenti-NC-infected hAMSCs or uninfected control hAMSCs ( Figure 3g ). Therefore, we demonstrated that overexpression of miR-216a not only promotes osteogenic differentiation in vitro but also facilitates ectopic bone formation in vivo.
miR-216a antagonizes the suppressive effect of DEX on osteogenic differentiation and is correlated with bone formation. It has been reported that long-term administration of glucocorticoids can lead to GIO. 35 Glucocorticoids suppress bone formation through their direct and indirect effects on osteoblasts.
2,3 DEX, an extensively used synthetic glucocorticoid, has been found to suppress osteogenic differentiation. 36 To clarify the effect of glucocorticoids on osteogenic differentiation, we used different concentrations of DEX to treat hAMSCs in the process of osteogenic differentiation. Using ALP staining, Alizarin red staining and qRT-PCR, we demonstrated that DEX suppressed the osteogenic differentiation of hAMSCs in a dose-dependent manner. When the DEX concentration was higher than 10 nM, it significantly inhibited osteoblast differentiation, as demonstrated by decreased ALP staining, reduced matrix mineralization, and suppressed expression of osteogenic factors and marker genes (Supplementary Figures S2A-C).
To investigate whether miR-216a overexpression can affect the inhibition of osteoblast differentiation caused by DEX in hAMSCs, we induced lenti-216a-infected hAMSCs into osteogenic lineage with osteogenesis induction medium containing 10 nM DEX. We found that the ALP staining and ALP activity were significantly enhanced by miR-216a overexpression (Figures 4a and b) . Alizarin red staining also showed that in vitro matrix mineralization increased in DEXtreated cells after miR-216a overexpression (Figure 4c ). In addition, the expression of the osteoblast-specific transcription factors and marker genes RUNX2, ALP, OPN, COL1A1 and IBSP were mostly rescued at mRNA and protein levels in lenti-216a-infected hAMSCs compared with lenti-NC-infected cells under DEX treatment (Figures 4d and e) . These results confirmed that miR-216a overexpression significantly rescued the inhibition effects of DEX on osteoblast differentiation.
Our findings provide new opportunities for the prevention and treatment of osteoporosis and other bone metabolismrelated diseases. We collected 67 clinical samples from osteoporosis patients of different ages and analyzed the correlation between the expression of miR-216a and that of the bone formation marker genes RUNX2, ALP and OPN (Supplementary Table S1 ). Results showed that the expression levels of these three bone formation marker Figure S3) . Furthermore, the expression of miR-216a was positively correlated with the expression of the bone formation marker genes RUNX2, ALP and OPN (Figure 4f ). To preliminarily assess the safety of miR-216 for clinical use, we determined the karyotype of miR-216a-overexpressed hAMSCs and their derived osteoblasts. The data showed normal karyotype in all of the miR-216a-overexpressed hAMSCs and their derived cells (Supplementary Figures S4A-C) . We also analyzed the proliferation and cell cycle of miR-216a-overexpressed hAMSCs by MTS and flow cytometry, respectively. We observed that miR-216a overexpression did not significantly affect the proliferation and cell cycle of hAMSCs (Supplementary Figures S5A-C) .
miR-216a directly targets c-Cbl. To gain insight into the molecular mechanisms by which miR-216a regulates the osteogenic differentiation of hMSCs, we predicted the potential targets of miR-216a using TargetScan and found that osteogenic-related genes c-Cbl, Smad7, NLK, CEBPG and TGFBR2 have miR-216a binding sites in their 3ʹUTR (Figure 5a and Supplementary Figure S6A) . To test whether miR-216a directly targets these genes, we constructed luciferase reporters that had either a wild-type (WT) 3ʹUTR or a 3ʹUTR containing mutant sequences of the miR-216a binding site. We found that overexpression of miR-216a remarkably inhibited the luciferase reporter activity of the WT c-Cbl 3ʹUTR and WT Smad7 3ʹUTR, but not that of the mutated 3ʹUTR or another geneʹs 3ʹUTR (Figures 5b and c and Supplementary Figure S6B) . Moreover, the expression of c-Cbl in hAMSCs was markedly downregulated at protein level, but not at mRNA level, after miR-216a overexpression, whereas mRNA and protein levels of Smad7 exhibited no significant difference between the lenti-miR-216a-and lenti-NC-infected groups (Figures 5d and e) . These findings suggest that miR-216a regulates c-Cbl expression at the post-transcriptional level in hAMSCs.
To determine whether miR-216a functionally targets c-Cbl in regulating hAMSCs osteogenic differentiation, we used two short hairpin RNAs (shRNAs) to knock down the endogenous expression of c-Cbl. The qRT-PCR and western blot analyses indicated that both shRNAs effectively suppressed mRNA and protein expression of c-Cbl (Supplementary Figure S7A) . However, Cbl-b, another Cbl family member, exhibited no significant changes at mRNA level by these two shRNAs (Supplementary Figure S7A) , suggesting the c-Cbl-specific suppression by these shRNAs. Next, using the c-Cbl shRNAs, we found that downregulation of endogenous c-Cbl remarkably promoted osteogenic differentiation in hAMSCs, as demonstrated by enhancement of ALP staining and ALP activity, promotion of matrix mineralization in vitro (Figures 5f-h ) and significant upregulation of the expression of the osteogenic regulators and osteoblast marker genes (RUNX2, ALP, OPN, IBSP and COL1A1) at mRNA and protein levels (Figures 5i and j) . Moreover, when endogenous c-Cbl was downregulated by specific shRNAs (sh-c-Cbl) in hAMSCs during osteogenic differentiation with DEX treatment, the suppressive effect of DEX on osteoblast differentiation was also significantly rescued (Supplementary Figures S7B-D) . The above results were consistent with those observed in miR-216a-overexpressed hAMSCs. 
miR-216a regulates the c-Cbl-mediated PI3K/AKT pathway during osteogenic differentiation in hAMSCs. c-Cbl is an adaptor protein and E3 ligase that has important roles in several signaling pathways that affect various cellular functions. 37, 38 Among them, the PI3K and STAT5 pathways have been reported to be involved in the regulation of bone formation and osteoblast differentiation by interacting with c-Cbl.
39-41 PI3K inhibitor LY294002 or STAT5 inhibitor SC-355979 was added into the osteogenesis induction medium during osteogenic differentiation of hAMSCs. We demonstrated that PI3K inhibitor LY294002 remarkably suppressed the osteogenic differentiation of hAMSCs in a concentration-dependent manner, which was confirmed by the reduction of ALP staining and ALP activity and downregulation of the PI3K/AKT signaling pathway-related molecular elements and osteogenic factors (Figures 6a-c) . However, STAT5 inhibitor SC-355979 showed no significant effect on this process (data not shown). Therefore, we focused on the PI3K pathway in subsequent experiments. Western blot showed that overexpression of miR-216a increased the expression levels of p85 and phospho-Akt, indicating that the PI3K/AKT signal pathway was enhanced (Figure 6d ). This finding was consistent with the effect of knockdown of c-Cbl with shRNAs on protein levels of p85 and phospho-Akt (Figure 6e ). In addition, the enhancement of hAMSC osteogenic differentiation by miR-216a overexpression was almost blocked by LY294002, as demonstrated by decreased ALP expression and ALP staining and ALP activity and reduced mineral deposition (Figures 6f-i) . Furthermore, the recovery effects of miR-216a on the inhibition of osteogenesis by DEX were also attenuated by the PI3K inhibitor LY294002 (Figures 7a-d) . Together, these results suggest that miR-216a regulation of osteogenic differentiation and bone formation of hAMSCs occurs via the c-Cbl/ PI3K signaling pathway (Figure 8 ).
Discussion
More and more miRNAs are found as negative factors involved in the regulation of osteogenic differentiation. 23, 26, 27 Only a few miRNAs have been found to promote osteogenic differentiation. 25, 42, 43 In this study, we first identified miR-216a as an important enhancer of osteoblast differentiation of hAMSCs and hucMSCs. In the case of bone formation, MSCs generate new osteoblasts and their progenitors, which are essential for bone homeostasis and fracture healing. 44, 45 Using a preclinical ectopic bone formation model, we found that miR-216a can effectively promote bone tissue generation in vivo, which suggested that miR-216a may be an effective agent for promoting bone tissue engineering, bone defect repair and fracture healing.
DEX, a widely used glucocorticoid, was shown to inhibit osteogenic differentiation and bone formation, 36, 46 and DEX redirects the differentiation of bone marrow stromal cells from the osteoblastic lineage to the adipocyte lineage. 36, 47 We found that when the concentration is higher than 10 nM, the osteogenic differentiation of hAMSCs can be significantly inhibited by DEX. In all, 10 nM of DEX was then used as the minimum effective concentration in vitro system to investigate protective factors for osteoporosis. Both DEX and miRNA were found to have important roles in the regulation of osteogenic differentiation. So far only miR-29a has been reported to ameliorate glucocorticoid-induced suppression of osteoblast differentiation by regulating Wnt/β-catenin pathway. 33, 34 In this study, we found that overexpression of miR-216a can significantly rescue the suppressive effects of DEX on the osteoblast differentiation of hAMSCs, which suggested that therapeutic upregulation of miR-216a in MSCs may promote bone formation and even reverse osteoporosis. With the development of miRNA delivery system, which can Damage of the bone formation potential of MSCs is responsible for the bone loss incurred in aging and osteoporosis. 10, 11 Recently, it was reported that elevated miR-214 levels correlated with a lower degree of bone formation in bone specimens from aged patients with osteoporosis. 26 Here we were the first to demonstrate that the expression of miR-216a was positively correlated with the expression of key marker genes of bone formation, further suggesting miRNAsʹ great value for the prevention and treatment of osteoporosis or other bone metabolism-related diseases.
Previously, it has been reported that miR-216a is a serum biomarkers of exocrine pancreas injury of acute pancreatitis. 48, 49 PTEN and Smad7 were identified to be the possible targets of miR-216. 48, 49 In this study, we found that although miR-216a can target the 3ʹUTR of Smad7, it has no significant effect on the protein level of this gene, which suggested that miRNAs have different targets in different cells and can act selectively in different cells. Here, we defined a new mechanism whereby miR-216a is involved in regulation the expression of c-Cbl protein at the post-transcriptional level.
c-Cbl is a member of the RING-type E3 ubiquitin ligase family, which has important roles in several signaling pathways that affect various cellular functions. 37, 38 Tyrosine 731 (Tyr 731 in humans; Tyr 737 in mice) is unique to c-Cbl and is phosphorylated by Src family kinases. Phosphorylated Cbl tyrosine 731 provides a docking site for the p85 regulatory subunit of PI3K, which has an important role in the regulation of bone homeostasis. 39, [50] [51] [52] It has been reported that abrogation of c-Cbl-PI3K interaction increase bone formation and osteoblast proliferation. 39, 40 We found that miR-216a functionally targets c-Cbl to regulate the osteogenic differentiation of hAMSCs. Overexpression of miR-216a or knockdown of its target c-Cbl can increase the expression of p85 and phospho-Akt, indicating the activation of the PI3K signaling Those findings demonstrate that miR-216a promotes osteogenic differentiation and rescues the suppressive effects of DEX on osteogenic differentiation of hAMSCs through the c-Cbl/PI3K signaling pathway. In summary, we are the first to confirm that miR-216a is positively correlated with bone formation and cannot only promote osteogenic differentiation in vitro and promote bone formation in vivo, but also can effectively antagonize the suppression of DEX on osteoblast differentiation, through repressing c-Cbl expression, which, in turn, results in the activation of the PI3K signaling pathway. Notably, our findings not only enrich the understanding of miRNA regulation of bone development and osteogenic differentiation, but also enable new opportunities for the bone tissue engineering, clinical bone defect repair, and especially the prevention and treatment of osteoporosis and other bone metabolism-related diseases.
Materials and Methods
Cell isolation, culture and osteogenic differentiation. Human adipose tissues were collected from donors who performed liposuction surgery. Human umbilical cords were obtained from normal full-term deliveries. All experiments followed the procedures approved by the ethics committee at the Chinese Academy of Medical Sciences and Peking Union Medical College. hAMSCs were isolated and cultured as previously described. 53 hucMSCs were generated as described previously. 54 To induce osteogenic differentiation, third-passage hAMSCs were seeded in six-well plates and treated with osteogenesis induction medium, which was high-glucose Dulbeccoʹs modified Eagleʹs medium containing 10% FBS (Gibco, Raritan, NJ, USA), 10 mM β-glycerophosphate (Sigma, St. Louis, MO, USA) and 0.2 mM ascorbic acid (Sigma). Assay for ALP activity. We applied the method that has been described previously. 55 The cells were washed three times with PBS and lysed in 10 mM Tris, pH 7.4, 0.2% Igepal and 2 mM phenylmethylsulfonyl fluoride. After sonication and centrifugation, the ALP activity in the supernatant was measured photometrically using the Alkaline Phosphatase Yellow Liquid Substrate System (pNPP, Sigma). Briefly, 5 μl of thawed cell lysates were incubated with 200 μl of the pNPP reagent for 30 min at 37°C. The reaction was blocked by adding 50 μl of 3 M NaOH. The photometric values were determined using a spectrophotometer at 405 nm. The ALP activity was normalized to the total protein of the cell lysates.
RNA extraction and qRT-PCR. Total RNA was extracted using TRIzol reagent (Invitrogen, Paisley, UK) and then was treated with DNase I (Ambion, Paisley, UK) at 37°C for 30 min. cDNAs were synthesized using a high-capacity cDNA reverse transcription Kit (Applied Biosystems, Foster City, CA, USA). For the qRT-PCR analysis of miR-216a, the TaqMan miRNA reverse transcription kit and TaqMan miRNA assay kit (Applied Biosystems) were used. The relative expression of mRNA or miRNA was evaluated by the 2 -ΔΔCt method and normalized to the expression of GAPDH or U6, respectively. miRNA microarray analysis. miRNA expression profiling was performed using the TaqMan Array Human MicroRNA Cards V3.0 (Applied Biosystems, P/N: 4444913) following the manufacturerʹs instructions. The detailed information about the platform can be found on ABI website (https://products.appliedbiosystems.com). Experiments were performed twice using uninduced hAMSCs and in triplicate using osteogenic-induced 4-day cells. Ten nanograms of total RNA was used for each reaction. The criterion to determine the expression of miRNA is based on the CT value. miRNAs with CT value 440 in all compared groups were filtered. Only data with P-value o0.05 were included for further analyses. The expression of each individual miRNA was plotted as average CT values for each sample minus the average values for U6 using the 2 − ΔΔCT method. The data were adjusted by log transformation, mean centering, median centering and then normalization. Hierarchical clustering was manipulated by using average linkage method with Person correlation as a distance. Clustering of data and heat-map representations were performed by using Cluster 3.0 and Treeview software (http://smd.princeton.edu/resources/restech.shtml). TaqMan qRT-PCR was used to validate the microarray data and the PCRs were performed at least in triplicate.
Western blot analysis. Cells were lysed in RIPA lysis buffer (Beyotime, Shanghai, China) with 1 mM PMSF and protease inhibitor cocktail on ice for 30 min, manually scraped from culture plates and then sonicated and quantified using the BCA Protein Assay Kit (Beyotime). Protein fractions were separated by 10% SDS-PAGE and then were transferred to polyvinylidene difluoride membranes (0.22 μm, Millipore, Billerica, MA, USA). The membranes were blocked with 5% BSA and incubated with specific antibodies overnight at 4°C and then were incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Immunodetection was visualized using a chemiluminescent ECL reagent (Millipore).
Ectopic bone formation in vivo. A total of 2 × 10 6 hAMSCs were mixed with wetted HA/TCP ceramic powder (80 mg; National Engineering Research Center for Biomaterials, Chengdu, China), incubated at 37°C overnight and implanted subcutaneously into the dorsal surface of 8-week-old NOD/SCID mice. 56 The implants were harvested at 8 weeks, fixed in 4% paraformaldehyde, decalcified in 10% EDTA and embedded in paraffin. Thin sections (5 μm) were stained with H&E.
Clinical bone specimen preparation. Sixty-seven clinical bone specimens were collected from the Orthopaedic Beijing Union Medical College Hospital. Patients who had a fracture caused by falling without obvious violence were included in our study (inclusive criteria). Individuals with diabetes, malignancy or other severe diseases in the previous 5 years were excluded from our study (exclusive criteria). All of the clinical procedures were approved by the ethics committee at the Chinese Academy of Medical Sciences and Peking Union Medical College.
Dual luciferase reporter system luciferase assay. An 80-to 100-bp synthetic fragment of the 3ʹUTR of c-Cbl, Smad7, NLK, CEBPG or TGFBR2 containing the putative miR-216a recognition element and corresponding mutated 3ʹUTR were subcloned into the psiCHECK-2 vector (Promega, Southampton, UK) downstream of the renilla luciferase reporter gene. Transient co-transfection of HEK293T cells (1 × 10 5 cells per well) with the luciferase reporter vector and miR-216a mimic or miR-negative control (miR-NC) was performed in 24-well plates using Lipofectamine 2000 (Invitrogen). The luciferase activities were measured 48 h after transfection using the Dual Luciferase Reporter Assay System (Promega), and each experiment was repeated in triplicate. The renilla luciferase activity was normalized to the firefly luciferase activity for each transfected well.
Statistical analysis. All of the numerical results are presented as the means ± S.D. Significant differences between groups were analyzed using Studentʹs t-tests. For multiple-group testing, analysis of variance was conducted followed by a posteriori t-testing. Differences were considered statistically significant at *Po0.05, **Po0.01 and ***Po0.001. 
